Endoscopic Retrograde Cholangiopancreatography Market

SKU: DMMI4200 | Last Updated On: Sep 21 2022 | Available Formats

>Endoscopic Retrograde Cholangiopancreatography Market Expected to reach at a high CAGR 8.7% by 2029:

Endoscopic Retrograde Cholangiopancreatography Market is segmented By Product Type(Endotherapy Devices, Imaging Devices, Endoscopes, Energy Devices and Others), By Application(Biliary Sphincterotomy, Biliary Dilatation, Biliary Stenting, Pancreatic Sphincterotomy, Pancreatic Duct Dilatation and Pancreatic Duct Stenting), By End-User(Hospitals, Ambulatory Surgical Centers, Specialty Clinics and Others), and By Region(North America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.

Endoscopic retrograde cholangiopancreatography market size was worth US$ XX million in 2020 and is estimated to reach US$ XX million by 2029, growing at a CAGR 8.7% during the forecast period (2022-2029). Endoscopic retrograde cholangiopancreatography is a radiologic imaging technique performed by combining both endoscopy and fluoroscopy to treat biliary disorders. This technique is majorly utilized for the diagnosis of certain disorders associated with pancreatic ductal systems.

Endoscopic Retrograde Cholangiopancreatography -Market Dynamics

Endoscopic retrograde cholangiopancreatography market growth is driven by the rise in incidences of gastrointestinal and chronic biliary disorders, increasing demand for minimally invasive surgeries and increase in frequencies of benign tumors of the liver and pancreas primarily drive the growth of the market.

The rise in incidences of gastrointestinal and chronic biliary disorders is expected to drive the market growth

Gastrointestinal (GI) diseases involve different parts of the GI tract and the accessory organs of digestion like the liver, pancreas, and gallbladder. GI disorders significantly affect millions of people and are considered a major cause of global morbidity and mortality. For instance, according to the International Foundation for Gastrointestinal Disorders Report published in 2019, GERD affects about one-third of the total population leading to bleeding problems driving the growth of the global market. In the USA, GI diseases affect 60–70 million citizens annually, 3 with the National Institutes of Health devoting up to $1.6 billion to GI research in 2017. On the other hand, primary biliary cholangitis (PBC) incidence is 5.8-15 cases per 1 million population. A large surge in fatality rate has drawn the attention of the governments, and hence the demand for treatment is set to increase in the forecast period.

Increasing frequencies of benign tumors of the liver and pancreas are expected to drive the market growth

Benign liver lesions are found in more than 20% of the general population, including haemangioma (4%), focal nodular hyperplasia (FNH, 0.4%) and hepatic adenomas (0.004%). On the other hand, it is estimated that 47,050 effects (24,640 men and 22,410 women) from pancreatic tumor occurs every year as per the Journal published on June 2021 in the National Institutes of Health. According to the American Cancer Society, pancreatic cancer is the ninth most common cancer in women and the tenth most common cancer in men. It is the fourth leading cause of cancer death in men and women. It accounts for 7% of all cancer deaths. As most pancreatic cancers (93%) are exocrine adenocarcinoma, 7% are pancreatic neuroendocrine tumors. This has resulted in great awareness about the danger, and hence, people opt for better treatment. As a result, the key medical organizations are set to invest more in endoscopic retrograde cholangiopancreatography, and this is projected to drive the market growth during the forecast period.

High costs associated with treatment from ERCP devices

For diagnostic ERCP, the disposable equipment accounted for 27% of reimbursement; disposable equipment accounted for 68% for therapeutic ERCP. Although overall reimbursement was higher for therapeutic ERCP, the very high direct costs related to disposable equipment limited the ability of reimbursement to cover indirect costs. For instance, according to the Massachusetts Medical Society, the annual fixed cost for the organization of the ERCP unit was $136,213. The mean variable costs were $344 for diagnostics units. Thus, it is anticipated to hamper the market growth during the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a major global impact on endoscopic services. Furthermore, the infection is transmitted through contact and droplets. Therefore, endoscopy providers face tremendous risk during the pandemic as the spread is mainly through direct contact or aerosol droplets, and endoscopy procedures require a short physical distance between patients and personnel. Based on experience with SARS, a report from Hong Kong reported that the risk of infection is 5% for physicians, 4% for nurses, and 8% for healthcare assistants. It emphasized the importance of practising strict isolation, infection control measures, and adherence to the use of personal protective equipment (PPE). Hence, the endoscopic retrograde cholangiopancreatography market is negatively impacted by the COVID-19 pandemic.

Endoscopic Retrograde Cholangiopancreatography Market Segment Analysis

The endotherapy devices segment is expected to hold the largest share in this market segment

Endotherapy devices are used to examine abdominal pain, ulcers, digestive tract bleeding, abnormal growths in the colon and other abdominal & gastrointestinal (GI) conditions.  The Coated endoscopy guidewire accounted for the majority of the market share owing to high demand. These products reduce friction, preserve tactile feel, and allow easy access. As a result, hydrophilic coated guidewires are highly used. This is owing to a high preference for hydrophilic coated guidewires in the ERCP procedures. This hydrophilic nature of the guidewires results in the chemical interaction with water to form a hydrogel material that exhibits low friction coefficients.

For instance, Key Surgical, a Hydrophilic guidewire, provides soft, kink-resistant coated shaft atraumatic delivery through the GI tract/orifices. In addition, Zebra-coating provides a clear vision for wire positioning and movement.

Endoscopic Retrograde Cholangiopancreatography Market



Market CAGR


Segments Covered

By Product Type, By Application, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

Endoscopic Retrograde Cholangiopancreatography Market Geographical Analysis

North America region holds the largest market share of the global endoscopic retrograde cholangiopancreatography market

North America is expected to dominate the overall endoscopic retrograde cholangiopancreatography market. This is due to the increased research in diagnostic imaging and pancreatic surgeries, development for technologically advanced ERCP devices in the market and increasing government investments for providing funds in healthcare have helped in the growth of Endoscopic Retrograde Cholangiopancreatography Market infrastructure. Also, due to high expenditure on R&D, the presence of major players & their product availability, and well-established healthcare infrastructure in the region. For instance, In October 2020, Olympus Corporation launched two new ERCP stone management devices, StoneMasterV and VorticCatchV. These devices are said to increase the efficiency in bile duct stone management and retrieval for endoscopic retrograde cholangiopancreatography (ERCP). Moreover, In January 2020, Olympus announced that the FDA granted clearance for the development of its duodenoscope with a sterile, disposable distal endcap.

Endoscopic Retrograde Cholangiopancreatography Market Competitive Landscape

The global endoscopic retrograde cholangiopancreatography market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Becton, Dickinson and Company, Olympus Corporation, Boston Scientific Corporation, CONMED Corporation, B. Braun Melsungen Ag, Cook Group Incorporated, Fujifilm Holding Corporation, Medtronic Plc, TeleMed Systems, Inc, Hobbs Medical, Inc and Ambu Inc. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the market globally.

For instance, In September 2019, FUJIFILM Medical Systems announced that the U.S. Food and Drug Administration (FDA) has issued clearance for six new endoscopes to be added to Fujifilm’s portfolio of endoscopic imaging solutions. These new endoscopes strengthen the company’s offering in core GI and ERCP solutions.

Global Endoscopic Retrograde Cholangiopancreatography Market – Market Key Companies to Watch

Boston Scientific Corporation

Overview: The company was founded in 1979. it has headquarters in the United States. It develops, manufactures, and markets minimally invasive medical devices. The company works through the segments MedSurg which includes Endoscopy, Urology and Pelvic Health, Rhythm and Neuro, Cardiovascular, Specialty pharmaceuticals. Globally the company has business in the US, EMEA, Asia-Pacific, Latin America and Canada.

Product Portfolio: SpyGlass DS System- It enables high-resolution imaging and therapy during an ERCP procedure to target biopsies, fragment stones through lithotripsy, and remove residual stones, stone fragments, and foreign bodies such as migrated stents.

Key Developments: In December 2019, Boston Scientific Corporation announced U.S. Food and Drug Administration (FDA) clearance of the EXALT Model D Single-Use Duodenoscope for use in endoscopic retrograde cholangiopancreatography (ERCP) procedures.

Frequently Asked Questions

What is the Projected CAGR value of the Endoscopic Retrograde Cholangiopancreatography Market?

Endoscopic Retrograde Cholangiopancreatography Market is expected to grow at a CAGR of 8.7% during the forecasting period 2022-2029.

Which region controlled the global market during 2022-2029?

North America region Controls the Endoscopic Retrograde Cholangiopancreatography Market during 2022-2029

Which is the fastest growing region in the Endoscopic Retrograde Cholangiopancreatography Market?

Among all regions, Asia Pacific is the fastest growing market share during the forecast period

Trending Topics

Endoscopic Clips Market

Capsule Endoscopy Market

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*

Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!